Investor Relations

Investor Relations

NASDAQCMMB
YearTrailing 12-MonthsCalendar Year 2026Calendar Year 2025Calendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2013Calendar Year 2012Calendar Year 2011
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Mergers & AcquisitionsProxy & Information StatementsOther
FormDescriptionDateFormat
SCHEDULE 13DSCHEDULE 13DJul 16, 2026Open SCHEDULE 13D in HTML.Open SCHEDULE 13D in DOC file.Open SCHEDULE 13D in PDF file.Open SCHEDULE 13D in XLS file.
SCHEDULE 13G/ASCHEDULE 13G/AFeb 17, 2026Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
SCHEDULE 13G/ASCHEDULE 13G/AFeb 10, 2026Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
SCHEDULE 13G/ASCHEDULE 13G/AAug 11, 2025Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
SCHEDULE 13G/ASCHEDULE 13G/AAug 7, 2025Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
SCHEDULE 13GSCHEDULE 13GAug 7, 2025Open SCHEDULE 13G in HTML.Open SCHEDULE 13G in DOC file.Open SCHEDULE 13G in PDF file.Open SCHEDULE 13G in XLS file.
About
Chemomab Therapeutics Ltd.

Chemomab is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug Phase 3 trial in PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND.

Join our mission.
Collaborate with us.

Collaborate with us.

We are actively seeking strategic collaborations and licensing opportunities that align with our therapeutic areas of focus.

To explore partnership opportunities, please contact us.

Quick
Links

© Copyright 2025 Chemomab Therapeutics Ltd. All rights reserved. Privacy Policy. Terms of Use. Cookie policy.

Site Design by Michael Kulwiec DesignLab.

Site Design by Michael Kulwiec DesignLab.